Aelis: AEF0217 showed encouraging efficacy signals in the phase 1/2 in DS
Aelis reported positive results for the phase 1/2 trial with AEF0217 in Down Syndrom patients, meeting the primary (safety), secondary (PK) and exploratory endpoints (efficacy). We view the safety data consistent with the one observed in prior phase 1 study in healthy candidates, which further vali
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.